Mainstream Media Claim: A CBD nose spray could soon transform seizure control for children with Dravet and Lennox-Gastaut syndromes.

Primary Journal Data: The publication is a narrative review of CBD, nanostructured lipid carriers, intranasal delivery, DS, and LGS literature through March 2026. It reports preclinical signals including higher brain targeting, increased brain-to-plasma ratios, longer central exposure, and anticonvulsant effects in animal seizure models, but no completed pediatric DS or LGS clinical trial of intranasal NLC-CBD.

Dr. Caplan’s Clinical Verdict: Promising delivery science, not clinical proof. Families should not substitute experimental intranasal CBD formulations for approved antiseizure treatment, but researchers should prioritize carefully monitored pediatric pharmacokinetic, safety, and efficacy trials.

Study Overview: Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are severe developmental epileptic encephalopathies that appear in early childhood, are unresponsive to medications, and have a dismal neurodevelopmental prognosis. Most patients do not respond well to polytherapy, and the need to fulfill this gap in clinical practice is urgent. Cannabidiol (CBD) has proven to be an effective adjunct drug, but oral preparations have low bioavailability, slow onset and systemic adverse effects. Nanostructured lipid carriers (NLCs) are an innovative therapeutic technology that can deliver CBD directly to the brain via the nose, enhance brain targeting, achieve faster onset, and minimize systemic exposure, which could be a valuable solution to current deficiencies in treatment.Intranasal NLC-CBD has preclinical evidence of increasing brain CBD levels, facilitating anticonvulsant action, and protecting against seizures in established animal models, like pentylenetetrazol-induced convulsions. NLC-based preparations have increased brain-to-plasma ratios and longer central exposure at lower doses in comparison to free or orally administered CBD. Despite these promising findings, there are still translational gaps to be addressed, such as insufficient safety data in the long term, disease-specific DS/LGS genetic models, inconsistencies in the pediatric nasal physiology, and conventional clinical dosing paradigms.Literature for this review was identified through searches of PubMed, Scopus, Web of Science, and Google Scholar, covering studies published up to March 2026 on CBD, NLC, intranasal drug delivery, DS, and LGS.There is a dire need to carry out properly designed clinical trials that would demonstrate the safety, pharmacokinetics (PK) and efficacy of intranasal NLC-CBD in DS and LGS. The first pediatric clinical trials, adaptive trial models and regulatory harmonization are necessary to convert this noble nanomedicine approach into a clinical therapy. Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare and severe forms of epilepsy which often start in childhood. A significant number of patients fail to respond to several antiseizure drugs, and have recurrent seizures. Cannabidiol (CBD) is a chemical found in the cannabis plant that is effective in reducing seizures, but there are some limitations in oral CBD products, including slow absorption and inconsistent efficacy and the possibility for drug interaction. In this review, a novel delivery system of delivering CBD to the brain via a nose spray containing nanostructured lipid carriers (NLCs) is investigated. The use of these tiny lipid-based particles can aid in the delivery of CBD to the brain more rapidly and effectively, avoiding the digestion process and lowering first-pass metabolism. Consequently, intranasal NLC-CBD is likely to have a quicker onset of effect, better brain penetration, and reduced doses. This review provides a summary of existing preclinical evidence, as well as safety and regulatory considerations and outlines the possible clinical development options for this technology. It also underscores some of the future possibilities, such as the application of artificial intelligence (AI), novel clinical trial designs, and combination therapies. While additional clinical trials are necessary, intranasal NLC-CBD is a promising approach for better seizure control, quality of life and treatment ease for DS and LGS patients and their caregivers.

Primary Source & Scope: Published in Therapeutic delivery (2026Sep17) conducted by Yashika, Sachin Yadav, Anish Arora, Nisha Bharti et al.. Primary Source Link | Primary Record: DOI: 10.1080/20415990.2026.2731738 | PMID: 42751849

Clinical research into Nanostructured lipid carriers for intranasal canna is progressing through rigorously documented peer-reviewed cohorts.

Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries.

The clinical need is unquestionably real. Dravet syndrome and Lennox-Gastaut syndrome are among the most difficult pediatric epilepsies we manage, and families often live with daily uncertainty despite polytherapy. Oral pharmaceutical CBD has earned a role because randomized trials showed seizure reduction, but its dosing can be constrained by gastrointestinal tolerability, somnolence, liver enzyme elevation, and drug interactions. A formulation that could deliver CBD more efficiently to the central nervous system while lowering peripheral exposure is worth studying seriously.

The key clinical discipline is not to let an elegant delivery concept outrun the evidence. Brain-to-plasma ratios and seizure protection in animal models are encouraging, but they do not tell us how a child with DS or LGS will absorb CBD through the nose during chronic use, especially with age-dependent anatomy, nasal illness, concurrent medications, and variable caregiver administration. I would view intranasal NLC-CBD as a legitimate translational candidate, not as a treatment option to recommend outside a properly designed trial.

Three Rules for Critical Reading